RU2019133284A - Лечение рака комбинацией лучевой терапии, наночастиц оксида церия и химиотерапевтического средства - Google Patents

Лечение рака комбинацией лучевой терапии, наночастиц оксида церия и химиотерапевтического средства Download PDF

Info

Publication number
RU2019133284A
RU2019133284A RU2019133284A RU2019133284A RU2019133284A RU 2019133284 A RU2019133284 A RU 2019133284A RU 2019133284 A RU2019133284 A RU 2019133284A RU 2019133284 A RU2019133284 A RU 2019133284A RU 2019133284 A RU2019133284 A RU 2019133284A
Authority
RU
Russia
Prior art keywords
cerium oxide
oxide nanoparticles
body weight
per kilogram
patient body
Prior art date
Application number
RU2019133284A
Other languages
English (en)
Russian (ru)
Inventor
Черил БЕЙКЕР
Original Assignee
БайоКьюрити Фармасьютикалз Инк.
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by БайоКьюрити Фармасьютикалз Инк. filed Critical БайоКьюрити Фармасьютикалз Инк.
Publication of RU2019133284A publication Critical patent/RU2019133284A/ru

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K33/00—Medicinal preparations containing inorganic active ingredients
    • A61K33/24—Heavy metals; Compounds thereof
    • A61K33/244—Lanthanides; Compounds thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/335—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin
    • A61K31/337—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin having four-membered rings, e.g. taxol
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/70—Carbohydrates; Sugars; Derivatives thereof
    • A61K31/7042—Compounds having saccharide radicals and heterocyclic rings
    • A61K31/7052—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides
    • A61K31/706—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides containing six-membered rings with nitrogen as a ring hetero atom
    • A61K31/7064—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides containing six-membered rings with nitrogen as a ring hetero atom containing condensed or non-condensed pyrimidines
    • A61K31/7068—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides containing six-membered rings with nitrogen as a ring hetero atom containing condensed or non-condensed pyrimidines having oxo groups directly attached to the pyrimidine ring, e.g. cytidine, cytidylic acid
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K33/00—Medicinal preparations containing inorganic active ingredients
    • A61K33/24—Heavy metals; Compounds thereof
    • A61K33/243—Platinum; Compounds thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0014—Skin, i.e. galenical aspects of topical compositions
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/10—Dispersions; Emulsions
    • A61K9/107—Emulsions ; Emulsion preconcentrates; Micelles
    • A61K9/1075—Microemulsions or submicron emulsions; Preconcentrates or solids thereof; Micelles, e.g. made of phospholipids or block copolymers
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Epidemiology (AREA)
  • Inorganic Chemistry (AREA)
  • Molecular Biology (AREA)
  • Organic Chemistry (AREA)
  • Dermatology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Biophysics (AREA)
  • Dispersion Chemistry (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Medicinal Preparation (AREA)
RU2019133284A 2014-07-17 2015-07-17 Лечение рака комбинацией лучевой терапии, наночастиц оксида церия и химиотерапевтического средства RU2019133284A (ru)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US201462025861P 2014-07-17 2014-07-17
US62/025,861 2014-07-17

Related Parent Applications (1)

Application Number Title Priority Date Filing Date
RU2017104909A Division RU2704811C2 (ru) 2014-07-17 2015-07-17 Лечение рака комбинацией лучевой терапии, наночастиц оксида церия и химиотерапевтического средства

Publications (1)

Publication Number Publication Date
RU2019133284A true RU2019133284A (ru) 2019-12-05

Family

ID=55079076

Family Applications (2)

Application Number Title Priority Date Filing Date
RU2019133284A RU2019133284A (ru) 2014-07-17 2015-07-17 Лечение рака комбинацией лучевой терапии, наночастиц оксида церия и химиотерапевтического средства
RU2017104909A RU2704811C2 (ru) 2014-07-17 2015-07-17 Лечение рака комбинацией лучевой терапии, наночастиц оксида церия и химиотерапевтического средства

Family Applications After (1)

Application Number Title Priority Date Filing Date
RU2017104909A RU2704811C2 (ru) 2014-07-17 2015-07-17 Лечение рака комбинацией лучевой терапии, наночастиц оксида церия и химиотерапевтического средства

Country Status (9)

Country Link
EP (2) EP3169312B1 (enExample)
JP (2) JP6706255B2 (enExample)
CN (2) CN111184733A (enExample)
AU (1) AU2015289504B2 (enExample)
BR (1) BR112017000800A8 (enExample)
CA (1) CA2955384C (enExample)
MX (1) MX387363B (enExample)
RU (2) RU2019133284A (enExample)
WO (1) WO2016011328A1 (enExample)

Families Citing this family (25)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US10512761B2 (en) 2009-12-02 2019-12-24 Renovorx, Inc. Methods for delivery of therapeutic materials to treat pancreatic cancer
WO2014197362A1 (en) 2013-06-03 2014-12-11 Ramtin Agah Devices, methods and kits for delivery of therapeutic materials to a pancreas
JP6706255B2 (ja) * 2014-07-17 2020-06-03 バイオキュリティー ファーマシューティカルズ インコーポレイテッド 放射線、酸化セリウムナノ粒子、及び化学療法剤の併用によるがんの治療
WO2017174437A1 (en) * 2016-04-05 2017-10-12 Hospital Clínic De Barcelona Ceria nanoparticles for use in the treatment of hepatocellular carcinoma
US11040027B2 (en) 2017-01-17 2021-06-22 Heparegenix Gmbh Protein kinase inhibitors for promoting liver regeneration or reducing or preventing hepatocyte death
AU2018253189A1 (en) * 2017-04-12 2019-12-05 Vikash J. BHAGWANDIN Compositions, packaged pharmaceuticals, and methods of using posaconazole for the sensitization of resistant tumors
EP3615067A1 (en) * 2017-04-28 2020-03-04 Seattle Genetics, Inc. Treatment of her2 positive cancers
US11052224B2 (en) 2017-05-18 2021-07-06 Renovorx, Inc. Methods for treating cancerous tumors
US10695543B2 (en) 2017-05-18 2020-06-30 Renovorx, Inc. Methods for treating cancerous tumors
US12290564B2 (en) 2017-05-18 2025-05-06 Renovorx, Inc. Methods and apparatuses for treating tumors
WO2019124603A1 (ko) * 2017-12-22 2019-06-27 경상대학교병원 Iwr-1을 유효성분으로 함유하는 켈로이드 예방 또는 치료용 조성물
KR102102535B1 (ko) * 2018-07-26 2020-04-21 서울대학교산학협력단 방사선 보호 나노입자
US20210338718A1 (en) * 2018-09-28 2021-11-04 The Regents Of The University Of Colorado, A Body Corporate Methods for preventing and treating pulmonary inflammation and fibrosis
RU2699670C1 (ru) * 2018-11-16 2019-09-09 Объединенный Институт Ядерных Исследований (Оияи) Способ повышения частоты образования двунитевых разрывов днк в клетках человека при действии ионизирующих излучений в условиях влияния радиомодификаторов
US20230218669A1 (en) * 2020-03-31 2023-07-13 Fred Hutchinson Cancer Center Augmenting antigen-negative cell death in antigen-targeted immunotherapies
US20230157299A1 (en) * 2020-04-30 2023-05-25 University Of Central Florida Research Foundation, Inc. Dispensable nanoparticle based composition for disinfection
WO2023025291A1 (zh) 2021-08-27 2023-03-02 深圳艾欣达伟医药科技有限公司 冻干制剂溶液及冻干制剂、方法和用途
JP7762796B2 (ja) 2021-08-27 2025-10-30 アセンタウィッツ ファーマシューティカルズ リミテッド Ｐａｒｐ阻害剤に耐性のある患者のｔｈ－３０２による治療
US20250186468A1 (en) 2022-03-15 2025-06-12 Ascentawits Pharmaceuticals, Ltd. Method for treating patient with brca-mutated cancer
EP4509127A4 (en) 2022-04-15 2026-07-15 Ascentawits Pharmaceuticals Ltd CANCER TREATMENT METHOD USING TH-302 ALONE OR IN COMBINATION WITH A PARP INHIBITOR
EP4529926A4 (en) 2022-05-23 2026-07-01 Ascentawits Pharmaceuticals Ltd CANCER TREATMENT METHOD BY COMBINATION OF AN ALKYLATING AGENT PRODRUGATION AND A CELL CYCLE INHIBITOR
CN119894521A (zh) 2022-09-22 2025-04-25 深圳艾欣达伟医药科技有限公司 乏氧激活的化合物在制备治疗癌症患者的药物中的用途
EP4674418A1 (en) 2023-02-27 2026-01-07 Ascentawits Pharmaceuticals, Ltd. Solution, freeze-dried formulation, freeze-dried formulation unit package, injection, and injection preparation method
EP4755396A1 (en) 2023-07-28 2026-06-10 Ascentawits Pharmaceuticals, Ltd. Treatment of p53 gene mutation or defect negative cancer and tumor patients
CN121985960A (zh) 2023-10-18 2026-05-05 深圳艾欣达伟医药科技有限公司 治疗p53基因突变阴性、kras基因突变阳性、brca突变阳性患者

Family Cites Families (15)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6099798A (en) 1997-10-31 2000-08-08 Nanogram Corp. Ultraviolet light block and photocatalytic materials
TWI323662B (en) * 2002-11-15 2010-04-21 Telik Inc Combination cancer therapy with a gst-activated anticancer compound and another anticancer therapy
WO2007002662A2 (en) * 2005-06-27 2007-01-04 Edward Via Virginia College Of Osteopathic Medicine Anti-inflammatory, radioprotective, and longevity enhancing capabilities of cerium oxide nanoparticles
JP2011522773A (ja) * 2007-12-27 2011-08-04 インフィニティ ファーマスーティカルズ、インク． 治療剤での癌の処置方法
WO2009132277A1 (en) * 2008-04-25 2009-10-29 The Board Of Regents Of The University Of Oklahoma Inhibition of neovascularization by cerium oxide nanoparticles
US20100015042A1 (en) * 2008-07-03 2010-01-21 Ramot At Tel Aviv University Ltd. Combine radiation therapy and chemotherapy for treating cancer
GB0921596D0 (en) * 2009-12-09 2010-01-27 Isis Innovation Particles for the treatment of cancer in combination with radiotherapy
WO2011109387A1 (en) * 2010-03-01 2011-09-09 Intraop Medical Corporation Radiotherapy combined with hypoxic cell sensitizers
US20120251496A1 (en) * 2011-03-31 2012-10-04 Telik, Inc. Ezatiostat for treating multiple myeloma
CA2869554A1 (en) * 2012-04-04 2013-10-10 Duke University Methods of using cerium oxide nanoparticles to mitigate or protect against radiation injury
DK2861212T3 (en) * 2012-06-13 2017-03-06 Cerion Llc Cerium oxide nanoparticles for the treatment of oxidative stress
EP2928877B1 (en) * 2012-12-06 2020-01-22 Merck Sharp & Dohme Corp. Disulfide masked prodrug compositions and methods
US10463734B2 (en) * 2014-04-25 2019-11-05 The Regents Of The University Of Michigan Nanoparticle therapy in cancer
JP6706255B2 (ja) * 2014-07-17 2020-06-03 バイオキュリティー ファーマシューティカルズ インコーポレイテッド 放射線、酸化セリウムナノ粒子、及び化学療法剤の併用によるがんの治療
GB201506381D0 (en) * 2015-04-15 2015-05-27 Isis Innovation Embolization particle

Also Published As

Publication number Publication date
RU2017104909A (ru) 2018-08-17
BR112017000800A8 (pt) 2023-04-25
CA2955384C (en) 2024-03-12
MX2017000578A (es) 2017-07-20
CN106604719B (zh) 2019-11-26
EP3169312B1 (en) 2020-09-02
EP3169312A1 (en) 2017-05-24
AU2015289504B2 (en) 2020-12-17
JP6706255B2 (ja) 2020-06-03
BR112017000800A2 (pt) 2018-07-03
EP3169312A4 (en) 2017-12-27
CA2955384A1 (en) 2016-01-21
JP2020158507A (ja) 2020-10-01
AU2015289504A1 (en) 2017-02-23
RU2704811C2 (ru) 2019-10-31
EP3628308A1 (en) 2020-04-01
MX387363B (es) 2025-03-18
CN106604719A (zh) 2017-04-26
WO2016011328A1 (en) 2016-01-21
JP2017521499A (ja) 2017-08-03
CN111184733A (zh) 2020-05-22
RU2017104909A3 (enExample) 2019-01-28

Similar Documents

Publication Publication Date Title
JP2017521499A5 (enExample)
JP2022009090A5 (enExample)
JP7025416B2 (ja) 好中球減少症を低減させるための組成物および方法
RU2012157805A (ru) Способы лечения рака мочевого пузыря
FI4397376T3 (fi) Yhdistelmä, joka sisältää mek-estäjän ja b-raf-estäjän
JP2022031331A (ja) 空間配置が変化した組換えインターフェロンを用いる腫瘍治療の方法
JP2014512356A5 (enExample)
RU2017104909A (ru) Лечение рака комбинацией лучевой терапии, наночастиц оксида церия и химиотерапевтического средства
RU2009121568A (ru) Комбинации и способы введения терапевтических агентов и комбинированная терапия
JP2006503919A5 (enExample)
CN104622794B (zh) 一种联合分子靶向药物和细胞毒药物的凝胶注射剂
JP2011503063A5 (enExample)
JP2018522028A5 (enExample)
JP2021513965A5 (enExample)
JP2009539994A5 (enExample)
AR070047A1 (es) Tratamientos terapeuticos contra el cancer. composicion que comprende un inhibidor de hedgehog.
JP2022527334A5 (enExample)
RU2018107930A (ru) Агонисты tlr4, их композиции и применение для лечения рака
RU2015152033A (ru) Нацеленные корролы, проявляющие опухолевую токсичность и предназначенные для мрт
RU2012108144A (ru) Противораковая терапия, направленная против раковых стволовых клеток и форм рака, устойчивых к лечению лекарственными препаратами
JP2015510945A5 (enExample)
JP2005508323A5 (enExample)
JP2016539149A5 (enExample)
WO2011113300A1 (zh) 能够抑制化疗药物引起的毒副反应的药物
JP2016502985A5 (enExample)